Romosozumab - UCB

Drug Profile

Romosozumab - UCB

Alternative Names: AMG-785; Anti-sclerostin; Anti-sclerostin monoclonal antibody; CDP-7851; EVENITY; Sclerostin Ab

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Developer Amgen; UCB
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Male osteoporosis; Postmenopausal osteoporosis
  • Discontinued Fracture

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Postmenopausal-osteoporosis(Combination therapy) in USA (SC, Injection)
  • 20 Oct 2017 Efficacy and safety data from the phase III FRAME trial in Postmenopausal osteoarthritis released by Amgen
  • 11 Sep 2017 Efficacy data from the phase III ARCH trial in Postmenopausal osteoporosis presented at the 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top